P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal Article
Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Jeffrey L. Wolf,Paul G. Richardson,Michael W. Schuster,Annette LeBlanc,Ian Walters,David S Battleman +5 more
TL;DR: Favorable observed response rates with bortezomib retreatment suggest that it may be a viable option for relapsed or refractory multiple myeloma, even in patients previously exposed to bortzomib.
Journal ArticleDOI
Daratumumab granted breakthrough drug status
TL;DR: DARA may, therefore, be the first mAb with significant anti-MM activity both as a monotherapy and in combination, as part of prospective clinical trials.
Journal ArticleDOI
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
Ajay K. Nooka,Michael Luhua Wang,Andrew Yee,Jonathan L. Kaufman,Jooeun Bae,Doris Peterkin,Paul G. Richardson,Noopur Raje +7 more
TL;DR: Overall, these results suggest that the PVX-410 vaccine is safe and immunogenic in this patient population and support continued study of PVx-410 in SMM.
Journal ArticleDOI
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
Yu-Tzu Tai,Liang Lin,Lijie Xing,Lijie Xing,Shih-Feng Cho,Shih-Feng Cho,Tengteng Yu,Chirag Acharya,Kenneth Wen,Phillip A Hsieh,John Dulos,Andrea van Elsas,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +14 more
TL;DR: Novel APRIL actions via TACI on Tregs and Bregs to promote MM cell survival are defined, providing the rationale for targeting APRIL/TACI system to alleviate the immunosuppressive BM milieu and improve patient outcome in MM.
Journal ArticleDOI
Lenalidomide in multiple myeloma.
TL;DR: Clinical trials demonstrate that lenalidomide, particularly in combination with dexamethasone, produces durable clinical responses in patients with relapsed and refractory disease and is generally well tolerated, with manageable toxicities.